Welcome to our dedicated page for HYPERFINE news (Ticker: HYPR), a resource for investors and traders seeking the latest updates and insights on HYPERFINE stock.
Hyperfine, Inc. (Nasdaq: HYPR) is a health technology and medical device company that focuses its news flow on developments around the Swoop® Portable MR Imaging® System, an FDA-cleared, portable, ultra-low-field brain MRI platform. Company press releases emphasize regulatory milestones, clinical studies, financial results, and global health initiatives tied to this AI-powered portable MRI technology.
Investors and clinicians following HYPR news can expect regular updates on clinical research and indication expansion efforts. Recent announcements include the enrollment of the first patient in the Contrast PMR study, a prospective, multi-center trial designed to evaluate contrast-enhanced ultra-low-field portable MRI to support a future FDA submission for expanded intended use of the Swoop® system with gadolinium-based contrast agents. Other clinical news has highlighted the PRISM PMR study, which evaluates the Swoop® system’s use in neurosurgical operating room settings, and a peer-reviewed publication describing the economic impact of integrating the Swoop® system into acute hospital care.
Hyperfine’s news feed also features regulatory and market access updates, such as regulatory approval of the Swoop® system in India by the Central Drugs Standard Control Organization (CDSCO), as well as CE Mark and UKCA Mark approvals for its Optive AI™ software. Financial and corporate news includes quarterly and preliminary unaudited financial results, capital raises through public offerings, participation in healthcare conferences, and business updates related to the commercial rollout of the next generation Swoop® system and Optive AI™ software.
For those tracking HYPR, the news stream provides insight into the company’s progress in hospital and neurology office adoption, its international expansion, and its collaborations on global brain health projects such as the UNITY initiative. Bookmarking this page allows readers to monitor how Hyperfine’s clinical, regulatory, and financial developments evolve over time.
Hyperfine Inc. has appointed Dr. Chip Truwit as the new senior medical director, enhancing its leadership for the growth of its portable MRI technology. Dr. Truwit, a seasoned expert in neuroradiology, previously led diagnostic imaging at Philips Healthcare. His extensive experience, including over 130 published articles and numerous patents, will support Hyperfine’s mission to broaden access to critical MRI imaging. This strategic move aims to improve hospital workflows and enhance care for underserved populations, especially children.
Hyperfine announces the deployment of its FDA-cleared portable MRI, Swoop, at M Health Fairview University of Minnesota Medical Center, marking a significant advancement in neurosurgery technology. This system allows for quick patient scans directly at the bedside, reducing wait times and transportation challenges. Swoop enhances patient safety and diagnostics with AI-driven capabilities, producing high-quality images in minutes. It has previously been deployed at various prestigious medical centers, further establishing its role in improving patient care.
Hyperfine (Nasdaq: HYPR) announced preliminary unaudited revenue figures for Q4 and the full year 2021, predicting revenues of approximately $0.362 to $0.437 million for Q4 and $1.42 to $1.50 million for the entire year. The company also secured $0.81 million in grant funding for Q4 and $1.45 million for the year. Despite challenges, Hyperfine installed over 50 Swoop devices in 2021, emphasizing growth potential in portable MRI technology.
Hyperfine (Nasdaq: HYPR) announces its participation in the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 1:30 p.m. ET. The company, known for its FDA-cleared portable MRI system Swoop®, strives to enhance patient access to diagnostic imaging. Interested parties can view the live and archived presentation on the company's investor website. The Swoop system enables rapid scans directly at the patient's bedside, providing critical imaging at a lower cost, making it a valuable tool for emergency departments, operating rooms, and intensive care units.
Hyperfine Inc. has completed its business combination with HealthCor Catalio Acquisition Corp. (Nasdaq: HCAQ), securing approximately $160 million in gross cash proceeds. This funding aims to accelerate the growth initiatives for its Swoop® portable MRI system, designed to enhance patient access to MRI technology. Trading under the ticker HYPR will commence on December 23, 2021. Hyperfine focuses on transforming medical imaging with Swoop, aiming to expand both domestically and internationally while addressing healthcare disparities.
Hyperfine and Liminal announced a definitive agreement for a business combination with HealthCor Catalio Acquisition Corp (Nasdaq: HCAQ). This merger creates a combined company valued at approximately $580 million, with expected cash resources around $375 million. The transaction aims to enhance accessibility and affordability in MRI imaging through Hyperfine's FDA-cleared Swoop™ device and Liminal's brain monitoring innovations. The merger is anticipated to close in Q4 2021, pending shareholder approvals and customary conditions.